28.02.2024 - Revance Therapeutics, Inc. (NASDAQ: RVNC), today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided a corporate update. Financial Highlights Total revenue for the fourth quarter 2023 was $69.8 .
Revance Therapeutics, Inc. today announced that the company will be participating in the following investor conferences.
Cowen 44th Annual Healthcare Conference
Chief Executive Officer, Mark Foley.
Innovis Asset Management LLC lifted its stake in Revance Therapeutics, Inc. (NASDAQ:RVNC – Free Report) by 266.1% in the third quarter, HoldingsChannel reports. The firm owned 38,501 shares of the biopharmaceutical company’s stock after purchasing an additional 27,984 shares during the period. Innovis Asset Management LLC’s holdings in Revance Therapeutics were worth $442,000 at the […]